In 2019, Scott Gottlieb, former Food and Drug Administration (FDA) commissioner, argued against throwing in the towel on biosimilars, as some other experts had advised. Gottlieb was right. The growth in biosimilar market share from late 2018 until now has been fairly remarkable.
Will 2021 Be Another Break-Through Year For Biosimilars?
